flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

Biocartis Group NV: Biocartis Announces Global Collaboration with Covance

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the global strategic commercialization agreement with Covance, LabCorp's Drug Development business. The agreement aims at offering the Idylla(TM) platform and its existing Idylla(TM) oncology assay menu[1] to Covance's customer base. Several Idylla(TM) instruments have already been placed at Covance sites in the US and China[2] to support global oncology trials. The agreement provides for additional placement of Idylla(TM) instruments at Covance sites globally to support customer needs for clinical trials and, when appropriate, to validate and implement companion diagnostic[3] applications.

Collaborations | 23 April 19
Read more
23
Apr
2019

Biocartis Group NV: Biocartis Announces Global Collaboration with Covance

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the global strategic commercialization agreement with Covance, LabCorp's Drug Development business. The agreement aims at offering the Idylla(TM) platform and its existing Idylla(TM) oncology assay menu[1] to Covance's customer base. Several Idylla(TM) instruments have already been placed at Covance sites in the US and China[2] to support global oncology trials. The agreement provides for additional placement of Idylla(TM) instruments at Covance sites globally to support customer needs for clinical trials and, when appropriate, to validate and implement companion diagnostic[3] applications.

22
Apr
2019

Vlaanderen investeert in gepersonaliseerde geneeskunde

Vlaams minister van Innovatie Philippe Muyters wil de Vlaamse farmaceutische, medische en de sector van de bio-, nano- en medische technologie aanzetten om de omwenteling van de gepersonaliseerde geneeskunde niet te missen. Het potentieel is groot, zowel voor de patiënten als de sector zelf. Voor goede projecten ligt er in totaal 10 miljoen euro klaar.

18
Apr
2019

Mithra announces new agreement with GSP for development of an additional injectable

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a new agreement with Generic Speciality Pharma (GSP) for the development and supply of a sterile hormonal injectable product at Mithra CDMO1. Headquartered in Dublin, GSP is part of the Alter Pharma group, a Belgian pharmaceutical conglomerate focused on the development and manufacturing of niche generics, complex generics and high added value products.

15
Apr
2019

VIB: Permit for CRISPR maize field trial that aims to measure climate stress

On April 12, 2019 VIB has been granted a permit for its field trial with maize plants that contain small surgical CRISPR-induced heritable changes. Obtaining this permit allows VIB to continue the field work that was already initiated in 2017

15
Apr
2019

MouSensor is now Yesse Technologies

MouSensor is very pleased to announce our official rebrand of the company from MouSensor to Yesse Technologies (strongly pronounced as Yes!).

23
Apr
2019

Biocartis Group NV: Biocartis Announces Global Collaboration with Covance

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the global strategic commercialization agreement with Covance, LabCorp's Drug Development business. The agreement aims at offering the Idylla(TM) platform and its existing Idylla(TM) oncology assay menu[1] to Covance's customer base. Several Idylla(TM) instruments have already been placed at Covance sites in the US and China[2] to support global oncology trials. The agreement provides for additional placement of Idylla(TM) instruments at Covance sites globally to support customer needs for clinical trials and, when appropriate, to validate and implement companion diagnostic[3] applications.

22
Apr
2019

Vlaanderen investeert in gepersonaliseerde geneeskunde

Vlaams minister van Innovatie Philippe Muyters wil de Vlaamse farmaceutische, medische en de sector van de bio-, nano- en medische technologie aanzetten om de omwenteling van de gepersonaliseerde geneeskunde niet te missen. Het potentieel is groot, zowel voor de patiënten als de sector zelf. Voor goede projecten ligt er in totaal 10 miljoen euro klaar.

18
Apr
2019

Mithra announces new agreement with GSP for development of an additional injectable

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a new agreement with Generic Speciality Pharma (GSP) for the development and supply of a sterile hormonal injectable product at Mithra CDMO1. Headquartered in Dublin, GSP is part of the Alter Pharma group, a Belgian pharmaceutical conglomerate focused on the development and manufacturing of niche generics, complex generics and high added value products.

15
Apr
2019

VIB: Permit for CRISPR maize field trial that aims to measure climate stress

On April 12, 2019 VIB has been granted a permit for its field trial with maize plants that contain small surgical CRISPR-induced heritable changes. Obtaining this permit allows VIB to continue the field work that was already initiated in 2017

15
Apr
2019

MouSensor is now Yesse Technologies

MouSensor is very pleased to announce our official rebrand of the company from MouSensor to Yesse Technologies (strongly pronounced as Yes!).

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?